These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Inhibition of syndecan-1 expression and function in oral cancer cells.
    Author: Muramatsu T, Saitoh M, Ro Y, Uekusa T, Iwamura E, Ohta K, Kohno Y, Abiko Y, Shimono M.
    Journal: Oncol Rep; 2008 Dec; 20(6):1353-7. PubMed ID: 19020713.
    Abstract:
    Syndecan-1 has been shown to be a prognostic factor in various types of tumors, suggesting its correlation with malignancy and metastasis. In the present study, we examined the expression of syndecan-1 in oral cancer cell lines and tested whether transfection of an siRNA against human syndecan-1 affected the malignant potential of these cells. Seven different human oral cancer cell lines (HSC2, HSC3, HSC4, Ca9-22, SAS, KB and BSC-OF) were used. To evaluate the mRNA expression of syndecan-1 in these cell lines, quantitative real-time RT-PCR (QRT-PCR) was carried out. In order to examine syndecan-1 function, siRNA was transfected into the cells, after which the cell growth rate and invasive ability were evaluated. As a negative control, a random sequence siRNA was used. QRT-PCR showed that syndecan-1 was expressed in Ca9-22 cells and that it was significantly higher (> 10-fold) than in the other oral cancer cell lines. Transfection of syndecan-1 siRNA was carried out on Ca9-22 cells, which increased their growth rate 1.4-fold above controls. The invasive ability of Ca9-22 cells treated with syndecan-1 siRNA was significantly higher (2-fold; n=5) than the controls. These results suggest that Ca9-22 oral cancer cells are a useful model to study syndecan-1 function and they show that syndecan-1 directly contributes to the growth and invasive ability of these cells.
    [Abstract] [Full Text] [Related] [New Search]